Table 6.
Scenario analysis results
| Scenario | Incremental QALYs (discounted) | Incremental costs (discounted), € | ICER, €/QALY |
|---|---|---|---|
| Healthcare perspective | 0.63 | 44,298 | 70,282 |
| Time horizon of 10 years | 0.49 | 46,761 | 95,307 |
| Combined OS fit: log-normal (best statistical fit) | 0.60 | 48,556 | 80,831 |
|
OS individual fits (best statistical fits) Avelumab + BSC: log-normal BSC alone: log-normal |
0.66 | 49,339 | 74,908 |
| PFS with avelumab + BSC: generalized gamma (second statistical fit) | 0.63 | 48,211 | 76,529 |
| PFS with BSC alone: log-logistic (second statistical fit) | 0.63 | 48,243 | 76,642 |
| TTD: treat to progression (including 2-year treatment stop) | 0.63 | 44,746 | 70,992 |
| Relative dosing intensity from clinical trial applied to avelumab costs | 0.63 | 39,352 | 62,434 |
BSC best supportive care, ICER incremental cost-effectiveness ratio, OS overall survival, PFS progression-free survival, QALY quality-adjusted life year, TTD time to discontinuation